Posted by Michael Wonder on 30 Jul 2024
ICER to assess treatment for acute pain
29 July 2024 - Report will be subject of Midwest CEPAC meeting in February 2025; draft scoping document open to public comment until 16 August 2024.
The ICER announced today that it will assess the comparative clinical effectiveness and value of suzetrigine (Vertex Pharmaceuticals) for the treatment of acute pain.
